The involved field is back: issues in delineating the radiation field in Hodgkin's disease.
about
The Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma.Role of Radiotherapy in Modern Treatment of Hodgkin's LymphomaTailored strategies for radiation therapy in classical Hodgkin's lymphoma.BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapyRadiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study.Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma.Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease.State-of-the-art issues in Hodgkin's lymphoma survivorship.The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.Modern radiotherapeutic strategies in the management of lymphoma.The concept and evolution of involved site radiation therapy for lymphoma.Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy.Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group.Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.Management and Prevention of Breast Cancer After Radiation to the Chest for Childhood, Adolescent, and Young Adulthood Malignancy.Noncoplanar intensity-modulated radiation therapy for young female patients with mediastinal lymphoma.Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience.
P2860
Q33778385-D3EDC59A-99CE-4E85-AEEB-4ED5EDD3BF0DQ34235785-C8F1DB90-4A86-47AD-9141-A098422B95A0Q34610653-2EC94231-257F-45E9-980F-C05075417D23Q34707420-6F0C5492-9B82-49DB-9AFB-6F900CC64798Q34774184-2CA8650A-DAA2-4D1D-B523-88B789262E50Q36299343-04A22427-C1B7-4F32-B9AB-FCEC43A2DE10Q36742694-C049F9D1-222A-4FBA-BF1D-ACAA65E0F306Q36791057-3EEA4DD6-F765-43AD-83D2-5F6D972053CAQ36898355-D92AA225-6179-49EA-A82F-D1E94B02B58BQ37782029-F30F56A6-3919-4F4F-B9CB-745B7A20FAADQ37934960-35668494-7F43-4CCC-91CF-F728BC80E63EQ38049331-C4ACD2FB-FABE-400B-BEFF-7BEA5C32956FQ38373945-FC955EA9-8010-4E19-8D52-416DFA5BA3FBQ38543470-97F7369A-C584-407B-9B13-8D18EC77517EQ38658450-1CA25EE1-CC4E-4A75-ACCD-C141A71F4E31Q38792217-0FC5B28A-4BAD-4C5E-945E-8DD016313F11Q39213429-3508FC31-B46E-49AA-A87E-F7AEC909F6DCQ39668341-0E941F96-C65F-423A-B6F6-7A08947AFC38Q47884628-F69C3BA9-38DE-451B-A16F-F35F5D964F3AQ49932419-D45D86B3-F266-42E3-89B5-249544DDBEA8Q51279958-C61E815A-5015-4D80-8A2A-8602E9ACF876Q51296655-57FBB152-7BCB-4C0F-9F93-0452BF421CE6Q53084551-BE6B36EF-3704-405A-B628-E05D254257B2
P2860
The involved field is back: issues in delineating the radiation field in Hodgkin's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The involved field is back: is ...... on field in Hodgkin's disease.
@ast
The involved field is back: is ...... on field in Hodgkin's disease.
@en
The involved field is back: is ...... on field in Hodgkin's disease.
@nl
type
label
The involved field is back: is ...... on field in Hodgkin's disease.
@ast
The involved field is back: is ...... on field in Hodgkin's disease.
@en
The involved field is back: is ...... on field in Hodgkin's disease.
@nl
prefLabel
The involved field is back: is ...... on field in Hodgkin's disease.
@ast
The involved field is back: is ...... on field in Hodgkin's disease.
@en
The involved field is back: is ...... on field in Hodgkin's disease.
@nl
P356
P1433
P1476
The involved field is back: is ...... on field in Hodgkin's disease.
@en
P2093
P356
10.1093/ANNONC/13.S1.79
P478
13 Suppl 1
P577
2002-01-01T00:00:00Z